169 related articles for article (PubMed ID: 30336729)
1. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
Morrow A; Garland C; Yang F; De Luna M; Herrington JD
J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
[TBL] [Abstract][Full Text] [Related]
2. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
[TBL] [Abstract][Full Text] [Related]
3. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
4. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
Bretagne M; Jouinot A; Durand JP; Huillard O; Boudou Rouquette P; Tlemsani C; Arrondeau J; Sarfati G; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2017 Jul; 80(1):45-53. PubMed ID: 28508095
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
Herrington JD; Tran HT; Riggs MW
Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
Millward MJ; Webster LK; Toner GC; Bishop JF; Rischin D; Stokes KH; Johnston VK; Hicks R
Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211
[TBL] [Abstract][Full Text] [Related]
7. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
8. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
Shepherd ST; Gillen G; Morrison P; Forte C; Macpherson IR; White JD; Mark PB
Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148
[TBL] [Abstract][Full Text] [Related]
9. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.
Dooley MJ; Poole SG; Rischin D; Webster LK
Eur J Cancer; 2002 Jan; 38(1):44-51. PubMed ID: 11750838
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin dosing for adult Japanese patients.
Ando Y; Shimokata T; Yasuda Y; Hasegawa Y
Nagoya J Med Sci; 2014 Feb; 76(1-2):1-9. PubMed ID: 25129986
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
Holweger K; Lipp HP; Beijnen JH; Bokemeyer C; Hartmann JT
Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060
[TBL] [Abstract][Full Text] [Related]
14. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care.
McLean L; Whittle JR; Graham J; Ismail H; Lichtenstein M; Hicks RJ; McNally O; Herschtal A; Rosenthal M; Rischin D; Hamilton A
Gynecol Oncol; 2020 Jun; 157(3):793-798. PubMed ID: 32220419
[TBL] [Abstract][Full Text] [Related]
16. The use of the Calvert formula to determine the optimal carboplatin dosage.
van Warmerdam LJ; Rodenhuis S; ten Bokkel Huinink WW; Maes RA; Beijnen JH
J Cancer Res Clin Oncol; 1995; 121(8):478-86. PubMed ID: 7642691
[TBL] [Abstract][Full Text] [Related]
17. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.
Cathomas R; Klingbiel D; Geldart TR; Mead GM; Ellis S; Wheater M; Simmonds P; Nagaraj N; von Moos R; Fehr M
Ann Oncol; 2014 Aug; 25(8):1591-7. PubMed ID: 24669017
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
van Warmerdam LJ; Rodenhuis S; ten Bokkel Huinink WW; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1996; 37(3):266-70. PubMed ID: 8529288
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
20. Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT-enhanced estimate of renal function.
Molenaar-Kuijsten L; Pieters TT; Veldhuis WB; Moeskops P; Rijkhorst EJ; Dorlo TPC; Beijnen JH; Steeghs N; Rookmaaker MB; Huitema ADR
Br J Clin Pharmacol; 2023 Oct; 89(10):3016-3025. PubMed ID: 37194167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
